Oncofocus
  • Services
    • Primary Market Research
    • Competitive Intelligence
  • About
  • Blog
  • Reports
  • Careers
  • Contact
“So it is said that if you know your enemies and know yourself, you can win a hundred battles without a single loss.
​If you only know yourself, but not your opponent, you may win or may lose.
​If you know
neither yourself nor your enemy, you will always endanger yourself.”
​- Sun Tzu from Art of War

Multiple Myeloma Indication

19/11/2019

 

BCMA CAR-T Pipeline Landscape ​

B-cell Maturation Antigen (BCMA) as an antigen has been shown to be specifically expressed in myeloma cells. With the ASH Annual Meeting 2019 close at hand, we performed a comprehensive pipeline analysis of BCMA targeting CAR-Ts in Multiple Myeloma indication.
Picture
Read More

Melanoma Indication

29/10/2019

 

PD-1/PD-L1 Combination Strategies

​Malignant melanoma is a complex, multifactorial disease, which is responsible for up to 75% of skin cancer related deaths globally.

With the US FDA approval of ipilimumab (CTLA-4 targeting agent) in 2011 for the treatment of advanced melanoma patients, clinical research intensity has gradually shifted towards Immune Checkpoint Inhibitors (ICIs) & their Combination agents. 

After the approval of nivolumab and pembrolizumab (both are PD-1 targeting agents), it is imperative to understand how PD-1/PD-L1 clinical landscape is evolving in melanoma.
​
Picture
Read More

All

8/4/2019

 

CAR-T Clinical Landscape Report

A lot has happened in the CAR-T field in the past 10 months since our last conference report on this technology. These include high-impact news such as EMA approval, and NICE recommendations for Kymriah and Yescarta.

As the ASCO 2019 Annual Meeting is less than a month away, we are publishing an updated CAR-T clinical landscape report. This year, in addition to updating the industry funded CAR-T pipeline, we have included non-industry funded CAR-Ts, as well. We believe this addition will give you a better picture of the current CAR-T clinical landscape. To keep the scope manageable, we have limited our research to only those CAR-Ts that are conducted in US and/or EU location(s).

We hope this report will help you get up to speed before the upcoming ASCO 2019 Annual Meeting.
Picture
Read More

    Categories

    All
    BCMA
    CARTs
    Cervical Cancer
    Melanoma
    Multiple Myeloma
    PD-1 And PD-L1
    Pipeline Landscape

    Archives

    November 2019
    October 2019
    September 2019
    April 2019
    August 2017

Bangalore Office
Oncofocus Solutions Pvt Ltd, 

#4, II Floor, 5th Main, 9th Cross, Jaya Mahal Ext,
Bengaluru
, India 56 00 46

Tel. +91 89044 00482

E-mail: support@oncofocus.com
RFQ: rfq@oncofocus.com
​

Singapore Office (Sales)
Oncofocus Solutions Pte Ltd, 

51 Goldhill Plaza, 
#07-10/11
​Singapore 30 89 00
​



E-mail: support@oncofocus.com.sg
​RFQ: rfq@oncofocus.com
​

    Subscribe to our Newsletter

Subscribe to Newsletter
Tweets by oncofocus
  • Services
    • Primary Market Research
    • Competitive Intelligence
  • About
  • Blog
  • Reports
  • Careers
  • Contact